Report : Europe Neurological Biomarkers Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product (Proteomics Biomarker, Genomics Biomarker, Metabolomics Biomarker, Imaging Biomarker, Others); Application (Alzheimer's Disease, Parkinson's Disease, Schizophrenia, Huntington's Disease, Spinal Muscular Atrophy, Others); End User (Pharmaceutical and Biotechnology Companies, Clinical Diagnostics, Research Organizations)

Rising Awareness Regarding Benefits of Early Diagnosis to Provide Growth Opportunities in the Neurological Biomarkers Market


According to a new market research study of ‘Europe Neurological Biomarkers Market to 2027 – Regional Analysis and Forecasts by Product, Application, and End User,’ the Europe neurological biomarkers market is expected to reach US$ 3,062.94 Mn in 2027 from US$ 1,221.15 Mn in 2019. The market is estimated to grow with a CAGR of 12.4% from 2020-2027. The report provides trends prevailing in the Europe neurological biomarkers market and the factors driving market along with those that act as hindrances.


The health systems are witnessing considerable improvement with respect to patient awareness regarding periodic check-ups and benefits of early disease diagnosis. The awareness of disease and symptoms is essential for early detection and screening. The awareness of public toward a neurological disease and its symptoms helps the healthcare professionals as they are more likely to take action to prevent it happening to them, or go to healthcare providers for check-ups.  Various local communities and non-government organizations (NGOs) are working toward organizing awareness campaigns to educate people regarding the benefits of early diagnosis. These organizations are conducting their campaigns with patient groups, hospitals and health organizations as well as publishing newsletters, magazines and other publications that aim to make people take healthy choices. This has eventually led to a preventive mentality among the local population, which is likely to offer growth opportunity for market players to tap on in the neurological biomarker industry.


The market is expected to witness a substantial growth due to driving factors such as rising prevalence of neurological disorders and progressive research in neurological biomarkers. However, the complications associated with the use of neurological biomarkers are expected to hinder the market growth.


Myriad Genetics, Inc., QIAGEN, Merck KGaA, Thermo Fisher Scientific, Inc. and Abbott are some of the leading companies operating in the Europe neurological biomarkers market.

Europe Neurological Biomarkers Market, By Regions, 2019 (%)

Europe Neurological Biomarkers Market, By Regions, 2019 (%)


The report segments Europe Neurological Biomarkers Market as follows:


Europe Neurological Biomarkers Market – By Product

  • Proteomics Biomarker
  • Genomics Biomarker
  • Metabolomics Biomarker
  • Imaging Biomarker
  • Others

Europe Neurological Biomarkers Market – By Application

  • Alzheimer’s Disease
  • Parkinson's Disease
  • Schizophrenia
  • Huntington's Disease
  • Spinal Muscular Atrophy
  • Others

Europe Neurological Biomarkers Market – By End User

  • Pharmaceutical and Biotechnology Companies
  • Clinical Diagnostics
  • Research Organizations

Europe Neurological Biomarkers Market– By Geography

  • Europe
    • Germany
    • UK
    • France
    • Italy
Contact Us
Contact Person: Sameer Joshi 
Phone: +1-646-491-9876
Email Id:    
  • Spain

Download Free PDF Brochure